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EXECUTIVE SUMMARY
The purpose of this study was to determine the impact of Hib vaccine on 
pneumonia and meningitis in children under the age of 1 year in the Klerksdorp 
district of the North West Province.
A record review was done to select cases under the age of 1 year admitted at 
Tshepong hospital with either pneumonia or meningitis. Two similar periods were 
compared in respect of the incidence of both conditions.
The study has shown a decline in the incidence of both pneumonia and 
meningitis after introduction of the vaccine. While the decline in the incidence of 
pneumonia was statistically significant, that of meningitis was shown to be 
insignificant.
The significant decline in the incidence of pneumonia is suggestive of the positive 
impact of the Hib vaccine.
It is recommended that:
• A similar study be conducted in the North West Province after 3 years of the 
introduction of the vaccine.
XI
• The impact of the Hib vaccine be measured on an ongoing basis using 
surveillance data.
• Other studies be conducted in the province and in the country to determine 
factors that may affect effectiveness of the immunisation programme and the 
impact of HIV/AIDS on the programme respectively.
xii
CHAPTER 1
INTRODUCTION AND ORIENTATION
1.1 Background
Communicable diseases remain one of the major health problems in 
developing countries today. These diseases are responsible for high rates 
of morbidity and mortality in the countries affected. The situation has been 
compounded by the HIV/AIDS pandemic which emerged in the past two 
decades, whereby these diseases take opportunities of compromised 
immune systems of individuals infected with HIV.1 Other compounding 
factors include the poor living conditions in which most people in less 
developed countries live. Countries experiencing civil wars and other 
forms of internal strife are at increased risk because of displacement of 
communities to over-crowded slum areas.2
Infections from Haemophilus Influenzae Type B (Hib) bacteria are among 
the major causes of severe bacterial diseases in unimmunised infants and 
young children under the age of 5 years in both developed and developing 
countries. Infection with Hib bacteria can cause pneumonia, meningitis, 
septicaemia, septic arthritis, osteomylitis, cellulitis, pericarditis and 
epiglottitis. Some of the children who survive the Hib disease suffer 
permanent disabilities such as blindness, deafness, and paralysis due to 
neurological impairment.3
In South Africa a Cape Town study estimated that 1 in 250 children under 
the age of 5 years become seriously ill from Hib disease and most children 
need hospitalisation to be treated.3
Pneumonia and meningitis due to Hib are common in children under the 
age of 1 year and mortality from meningitis is high.4 In developed 
countries about 5% of children with Hib meningitis die, while the case 
fatality rate in developing countries may be up to 47%. In South Africa the 
Cape Town study also established that 1 in 11 children who become 
infected with Hib will die and the case fatality rate may differ between 
provinces.
According to Children’s Vaccine Initiative 1998 5, the first modern Hib 
vaccine, appeared in the health scene about a decade ago. This Hib 
conjugate vaccine, unlike its unconjugated predecessors has proven to be 
effective and efficacious against Hib disease in both developed and 
developing world settings. Mulholland et al 1997 4 also maintain that 
“protein polysacccharide conjugate vaccines have been highly effective in 
reducing Hib disease and carriage in industrialised countries”. In 1974 the 
World Health Organisation (WHO) introduced a successful programme 
known as the “Expanded Programme on Immunisation” (EPI), with the
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objective of expanding immunisation services beyond smallpox, with the 
emphasis of providing these services for children in developing 
countries.0 At the beginning of the programme, six vaccine preventable 
diseases were included in the EPI: tuberculosis, diphtheria, pertussis, 
tetanus, polio and measles. Subsequently two more vaccines were 
included in the routine EPI schedule during the 1990s. These were yellow 
fever and hepatitis B vaccines. Yellow fever vaccine was introduced in the 
EPI programme in countries where this disease posed a risk. Hepatitis B 
vaccine was introduced gradually with a target date of 1997 for its 
incorporation in the immunisation programme of all countries.6 In 
countries where neonatal tetanus is an important cause of infant mortality, 
immunisation of women of child bearing age, especially pregnant women 
is recommended. The policy for neonatal tetanus elimination in South 
Africa is in line with this recommendation.7
WHO/EPI/Gen 1993 6 further states that the immunisation schedule in 
each country is consistent with epidemiology of diseases against which 
immunisation is provided, and within the capacity of the vaccine delivery 
system. It is thus important for immunisation programmes considering 
inclusion of additional vaccines as part of their routine immunisaton 
schedules to evaluate the epidemiological patterns of the target diseases 
in their country, as well as additional resources required for the 
introduction of the new vaccine to ensure cost effectiveness and sustained
3
supply and distribution respectively. The first priority for routine 
immunisation programme is to ensure that infants are immunised against 
the target diseases with appropriate primary immunisation at the youngest 
age possible.
In South Africa, hepatitis B vaccine was introduced as part of the 
immunisation programme in 1995, but yellow fever vaccine has never 
been part of the programme since it is not endemic in the country.7 
South Africa therefore currently provides eight vaccines in its EPI 
programme.
The lastest vaccine to be introduced in the South African EPI programme 
is Haemophilus Influenzae Type B (Hib) vaccine, on 1 July 1999. Three 
doses are given to each child at the age of 6, 10 and 14 weeks. 
Reconstitution of the Hib vaccine with diphtheria, tetanus and pertussis 
(DTP) vaccine takes place at the point of immunisation so as to administer 
DTP-Hib combined vaccine in one injection to every eligible child. The 
vaccine is given at the same time with Hepatitis B and polio vaccines.
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The North West province in South Africa also participated in the national 
initiative of Hib implementation which started on 1 July 1999 in all the 
public sector health clinics. The vehicle for Hib implementation is the EPI 
programme.
The EPI is a vertical programme at provincial level, headed by the 
programme manager (EPI Coordinator) at an Assistant Director level. The 
EPI unit is located in the Sub-Directorate: Communicable Diseases 
Control, which is in turn located in the Directorate: Health Programmes.
Policies for the EPI programme are developed at national level with inputs 
from provinces. Implementation takes place at provincial level within the 
District Health System structures. The actual immunisation thus takes 
place as an integral part of primary health care activities in each clinic. 
Participation of hospitals in the EPI is confined to immunisation with BCG 
and polio drops at birth as well as catch up immunisations for admitted 
children and those consulting at out-patient departments.
The provincial EPI Coordinator champions the whole process of policy 
implementation at all levels and provides technical support to district 
coordinators in the 18 health districts of the province. At district level EPI 
uses Communicable Disease Control Coordinators (CDCs) for policy 
implementation at facility (clinic and hospital) level. Each district has a
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CDC who is not only responsible for the EPI, but for all communicable 
diseases in the district. The role of CDCs in the EPI include, among 
others, training and technical supervision of vaccinators, EPI disease 
surveillance, outbreak response and ad hoc projects such as measles and 
polio campaigns and introduction of new vaccines.
Primary Health Care services in the Klerksdorp district where the study 
site is located are rendered by 18 fixed clinics, 16 of which belong to the 
local authorities and 2 to the province. The local authority thus plays a 
pivotal role in Primary health Care service delivery in this district. There 
are seven mobile teams serving mainly the farming areas of Klerksdorp. 
Of the seven mobile teams, four belong to the local authority and depart 
from three fixed local authority clinics every morning. Three of the seven 
teams belong to the province and are accountable to the Assistant 
Director of Community Health Services at the Klerksdorp district office 
where they converge every morning before leaving for their various 
stations.
Vaccine logistics and related functions are handled by the Directorate of 
Pharmaceutical Services. The function of procurement, management and 
distribution of drugs including vaccines up to district depots was 
outsourced to a private company: Vuna Health Care Logistics (VHL) since 
October 1999. The Department is thus still responsible for management
6
and distribution of vaccines from hospitals which are the current 
distribution points for clinics.
1.2 Study site
The study was conducted in the North West province (map1).8 The 
province comprises areas of the former Western Transvaal, 
Bophuthatswana and part of the Cape Province. According to the 1996 
population census, the population is 3,4 million (table 1).9 There were 75 
124 (2.2%) children under the age of 1 year in 1996. This number 
constitutes the target population for primary vaccine series in 
immunisation. About 70% of the population live in rural areas where 
distances from health facilities are vast, and transport poses one of the 
major problems.
The economy of the province relies heavily on mining, with resultant 
migration to towns for job seeking. Continuous migration and the seasonal 
movement of farm workers make it difficult to maintain and assess the 
effectiveness and efficacy of health services including immunisation.10
The Department of Health established its new boundaries after 1994. 
According to these boundaries, the province was divided into five regions, 
but have been recently reduced to four, with the merge of two regions of 
the Eastern side of the province (Odi and Rustenburg).11 The regions were
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sub-divided into 18 districts. Boundaries of the health districts were
coterminous with those of magisterial districts, the only difference being 
that Christiana and Schweizer-Reneke magisterial districts formed one 
health district.8 These boundaries are expected to change in the near 
future with the implementation of the new boundaries resulting from the 
demarcation process presently taking place in the country. A list of regions 
and districts in those regions is as follows:
A. Mafikeng
Mafikeng
Lichtenburg
Zeerust
Delareyville
B. Klerksdorp
Klerksdorp
Potchefstroom
Ventersdorp
Wolmaransstad
C. Rustenburg
Rustenburg
Mogwase
Odi
Moretele
D. Vryburg
Vryburg
Kudumane
Taung
Ganyesa
Schweizer-Reneke
Map 2 shows the location of primary health care facilities in the Klerksdorp 
region.8
The Klerkdorp district has the third largest population after Moretele and 
Rustenburg according to the 1996 population census.9 About 10% of the 
population (334 497) live in this district. Children under the age of 1 year 
constitute 2% (6362) of the district population. Using the 2.3% provincial 
growth rate, the population under the age of 1 year was estimated at 6811 
in 1999 and 6968 in the year 2000 (table 2). 9
9
The facility where the study was conducted is Tshepong hospital. This is 
one of the two public sector hospitals in the district. The other hospital, 
Klerksdorp is a provincial hospital and serves as a referral point for the 
entire Klerksdorp region and in some instances for the province. 
Tshepong is a district hospital situated in a small township of Jouberton 
just in the outskirts of town. Before 1994, Klerksdorp was a whites only 
hospital while Tshepong served mainly black patients. The two hospitals 
are, however, under the same management and are known as Klerksdorp/ 
Tshepong complex. Rationalisation of services in these institutions took 
place in May 1999, when Tshepong was identified as a district hospital 
and Klerksdorp as a provincial hospital both serving all racial groups. 
During the process of rationalisation paediatric wards of both hospitals 
were merged and the responsibility of paediatric medical care for the 
entire district given to Tshepong hospital. The implication is that there is 
no paediatric ward at Klersdorp hospital presently, and Tshepong caters 
for all medical care needs of all children in the district who require level 1 
medical care in the public sector. As this happened in the middle of the 
study it may have had substantial impact on results in terms of 
accessibility to paediatric care.
There are three private hospitals in the district. According to a report of 
Centre for health Policy of the university of the Witwatersrand 1997 12, 21 
percent of the population in the Klerksdorp district belong to medical aid
10
schemes. This implies that about 21 percent of the population in this 
district obtain their health services from the private sector.
Statement of the problem
It is estimated that 1 in 250 (5 729) children under the age of 5 years in 
South Africa become seriously ill from Hib disease every year. Most of 
these children are treated in hospital. Data from the Cape Town study 
suggests that 20% of survivors have permanent brain damage, mainly 
from Hib meningitis.3
Death from Hib disease is especially common in children under the age of 
1 year. Most deaths occur as a result of Hib meningitis, pneumonia or 
septicaemia.3
Immunisation with Hib vaccine is the only way of protecting children 
against Hib disease. Until 1 July 1999, only those parents who could 
afford to pay their private practitioners for the expensive vaccine were able 
to protect their children from Hib disease in South Africa. From 1 July 
1999, the Hib vaccine was introduced as part of the routine immunisation 
schedule for all public clinics participating in immunisation. The vaccine is 
given to all children visiting those clinics at 6, 10 and 14 weeks.13
The impact of Hib vaccine in South Africa is not known. The aim of this 
study was to determine the impact of this vaccine on the incidence of 
pneumonia and meningitis in children under the age of 1 year in the 
Klerksdorp district of the North West Province.
1.4 Rationale for the study
This study sought to determine the impact of Hib vaccine on clinical cases 
of pneumonia and meningitis in the Klerksdorp district. Based on the 
information gained from the literature review, the researcher made an 
assumption that the Hib vaccine should result in a decline on the overall 
incidence of clinical pneumonia and meningitis as the number of Hib 
specific cases decline.
Intervention strategies for disease control require that effective 
surveillance systems be put in place so as to determine the impact of 
these interventions.
Hib disease was made notifiable in South Africa since 1994.14 The current 
notification system, however, relies solely on the notification of a clinical 
diagnosis by a health worker without taking the laboratory component into 
consideration. In diseases such as Hib, this is quite questionable, as the 
clinical diagnosis of for example, Hib pneumonia would not differ from the
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clinical diagnosis of other acute bacterial pneumonia. This has caused 
formidable underreporting of Hib disease in the notification system.15
A laboratory surveillance system for Hib meningitis in South Africa was 
introduced in 1994 when the disease was made notifiable.13 The system 
was, however not well established in most parts of the country until 1999 
after the Hib vaccine implementation. Hib diseases have thus been under­
reported. The result is that there is no reliable baseline data against which 
comparison can be made since the laboratory surveillance system is now 
in place. Furthermore, the surveillance system is only for Hib meningitis, 
but there are other forms of Hib infections such as Hib pneumonia for 
which laboratory confirmation is not available.
In the absence of a comprehensive laboratory surveillance system, Hib 
vaccine was introduced as part of routine immunisation on 1 July 1999. It 
became advisable for the researcher to use other means on a small scale 
of determining the impact of this vaccine within a short period after its 
implementation. Pneumonia and meningitis were chosen because they 
are the most common Hib diseases in South Africa. It was found, during 
the process of the study that Tshepong hospital was one of the few that 
had established laboratory surveillance of Hib meningitis before 1999. 
Although this study sought to compare clinical cases of pneumonia and 
meningitis before and after introduction of the Hib vaccine, laboratory
13
surveillance was used to confirm Hib specific meningitis cases, as it 
provided an accurate picture of the disease incidence for periods under 
review (see annexure). Clinical diagnosis was solely used for cases of 
pneumonia.
1.5 Ethical considerations
Following approval of the research protocol by the post graduate and 
ethics committees of the university, permission and approval to conduct 
the study was sought from the Deputy Director General of the Department 
of Health in the North West Province. Permission was also obtained from 
the Tshepong hospital management (see annexures).
The staff in the paediatric ward at Tshepong hospital was orientated about 
the study with regard to its rationale, the time frames and their role in the 
process. It was further explained that no staff member would be punished 
in any way as a result of the study.
Since secondary data was used in the form of records, no individuals were 
interviewed and thus no consent was obtained from individuals 
participating in the study. Names of patients were not included at any 
stage of this study. Patient admission numbers were used solely to ensure 
that duplication of reporting does not occur.
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1.6 Aim and objectives
The aim of this study was to determine the impact of the Hib vaccine on 
the incidence of hospitalised cases of clinical pneumonia and meningitis 
among children under the age of 1 year in the Klerksdorp district of the 
North West Province.
The study objectives were as follows :
1 .6.1 To determine the demographic (age) characteristics of children admitted 
with either clinical pneumonia or meningitis at Tshepong hospital in 
Klerksdorp district.
1.6.2 To compare the number of incident cases of clinical pneumonia under the 
age of 1 year admitted at Tshepong hospital for a period of 6 months 
before and 6 months after the introduction of the vaccine.
1.6.3 To compare the number of incident cases of clinical meningitis under the 
age of 1 year admitted at Tshepong hospital for a period of 9 months 
before and 9 months after introduction of the vaccine.
1.6.4 To determine the Hib immunisation status of children admitted with either 
pneumonia or meningitis.
1.6.5 To determine the number of doses and interval between doses for 
immunised children admitted with either pneumonia or meningitis.
CHAPTER 2
LITERATURE REVIEW
Hib immunisation is provided through the Expanded Programme on 
Immunisation (EPI). EPI is one of the eight components of Primary Health 
Care (PHC). Primary Health Care thus formed the point of departure for 
literature that was reviewed, so as to get a broader perspective of the field 
in which immunisation in general, and specifically Hib immunisation and its 
impact on target diseases take place. Reports and articles on primary 
Health Care, Expanded Programme on Immunisation and Hib diseases 
and the vaccine, and studies on the impact of Hib were investigated to 
establish commonalities and differences, but most importantly to 
determine previous studies done on the topic being researched and 
relationships of the findings of those studies with this one.
2.1 International perspective of primary health care.
Dennill et al 1995 16 state that the concept of primary health care was 
developed as a means to urge governments of several countries to 
rationalise their highly technical approach to health care and to broaden 
their coverage by providing better basic services. Despite this move, 
health care throughout the world continued to have fragmented systems 
with trends towards expensive treatment for a few ill people rather than
16
preventive and promotive health care for many. These inequalities were 
found in both developed and developing countries worldwide.
In response to the international sense of despair regarding inadequate 
health care, an international conference on Primary Health Care, jointly 
sponsored by the World Health Organisation (WHO) and the United 
Nations Children’s Fund (UNICEF) was hosted by the government of 
USSR at Alma-Ata in 1978. At the end of the conference a declaration of 
intent was drawn up. The declaration succinctly outlined the principles and 
components through which any primary health care service can be 
universally established.16
2.1.1 Principles underlying a successful primary health care strategy
According to Denill et al 1995 16, a successful primary health care strategy 
is underpinned by six principles: access, equity, affordability, availability, 
effectiveness and efficiency.
There should be a comprehensive access to primary health care services 
which involves geographical, financial and functional access. Services 
should be within a reasonable distance from where the people using them 
live. WHO recommends 5 -  10 km and transport should be available. 
Costs should be in such a manner that users of services are able to pay
17
for them, and the services rendered must be appropriate to the health 
needs of the population as well as being culturally acceptable.16
People should have equal access to basic health care and social services. 
Emphasis should be placed on the disadvantaged such as people in rural 
areas, poor people and others who are at greatest risk for health 
problems.17 Of greater importance is the fact that primary health care 
services should be aligned with what the community and the country can 
afford. No person should be denied health care because of their inability to 
pay.
There should be sufficient and appropriate services to meet the health 
care needs of each community. The services provided must do what they 
were intended to do, and the results attained should be proportionate to 
the input, in terms of effort expended, money, time and other resources.16
2.1.2 Other important concepts for a successful primary health 
care strategy.
Community involvement and participation.
The key concept in primary health care is the involvement of the 
community in needs assessment, plans to address identified needs, 
implementation of plans and evaluation of the whole process. The global 
polio eradication initiative has a good example of the real sense of
18
community participation and its benefits. For example, the independent 
commission (Taylor Commission), established in 1992 by the Pan 
American Health Organisation found that the greatest positive impact of 
polio eradication was on social mobilisation and intersectoral 
collaboration.18 Social mobilisation strategy involved strengthening 
existing community organisations, the widespread use of education 
campaigns involving the mass media and political and community leaders. 
The approach ensured that communities were not only motivated to bring 
their children to be immunised during national immunisation days, but they 
also became actively involved in the campaign by helping to deliver the 
vaccine and maintain the cold chain, often making available their own 
vehicles, refrigerators and ice boxes. The business community heavily 
supported the National Immunisation Days in the Phillipines from 1993 to 
1996, through funding, allowing establishment of immunisation posts in 
fast food outlets, petrol stations, shopping malls, radio and television 
stations, bus and railway stations, government offices, schools and 
hundreds of company clinics.18
Of importance as well is the findings of the Taylor Commission on the 
impact of polio eradication campaign on health systems in the Americas. 
The Taylor Report pointed out that the polio eradication campaign 
established a culture of immunisation and served to improve
19
communication between health services staff and local communities, 
which in turn enhanced community participation.18
Intersectoral collaboration.
Primary health care, according to Lancaster 1988, 17 recognises that the 
health of a community cannot be improved by interventions within the 
health sector alone. Other sectors are equally important, and, in some 
cases more so, in promoting the community’s health and self reliance. For 
example, education, environment, industry, housing and nutrition are 
interrelated with health. These sectors need therefore to work together in 
a coordinated manner to ensure that they contribute to the health of the 
population and to avoid conflicting or duplicating efforts.
Intersectoral collaboration and community participation were found to be 
the twin pillars of primary health care and two strategies that had proved 
very difficult to implement in the Latin American countries before the polio 
eradication campaign which provided a base for development and 
implementation of these strategies.18
Disease prevention and health promotion
Emphasis in primary health care is on disease prevention and health 
promotion rather than curative services. Programmes such as
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immunisation form the pillar of preventive services, while provision of 
health information provide a good measure for health promotion.17
Appropriate technology.
Appropriate technology is defined by National Science foundation in 
Lancaster 1988 17 as “health care that is relevant to the needs and 
concerns of people, as well as being acceptable to them”. Costs, 
affordability of services within the context of existing resources such as 
number and type of health professionals and other workers, equipment, 
supplies and their distribution patterns through the community are all 
essential elements of appropriate technology.
GOBI -  FFF
Three years after Alma-Ata the United Nations Children's Fund introduced 
a programme called “Child Survival Revolution”. The objective was to 
reduce the high morbidity and mortality of infants and children in the 
developing world, since the improvement in the welfare of children was 
very limited despite the introduction of primary health care. Four activities 
were recommended to accomplish the child survival revolution strategy:
• G -  Growth monitoring
• O -  Oral rehydration
• B -  Breastfeeding
• I -  Immunisation
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Subsequently, UNICEF and interested parties agreed that the emphasis 
first be placed on immunisation, to be followed by oral rehydration and 
other phases as soon as possible. This agreement was expanded by the 
introduction of three more activities additional to the original four. These 
were:
• F -  Food supplementation
• F -  Female literacy
• F -  Family planning
Despite the wide criticism of this programme it was universally accepted 
as an integral part of primary health care.10
2.1.3 Trends in the Global Strategy of Primary Health Care
Many of developed countries have made substantial progress in bringing 
health services to their people. An ageing population has emerged in 
these countries because of an increased life expectancy, resulting in a 
shift in health problems to more chronic conditions. Rapid urbanisation 
has also affected health needs, with problems related to new lifestyles, 
high risk behaviour and deteriorating environments. The emphasis of the 
services in these countries is to meet these new needs and to reduce 
socio-economic disparities.16
Dennill et al 1995 16 further state that developing countries have also 
made significant progress in establishing a health infrastructure based on
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primary health care. As the programme evolves and needs are met, new 
health needs similar to those in developed countries emerge, and these 
need to be addressed, often under constraints of resources. Some 
developing countries continue to struggle with very high infant and 
maternal mortality rates and alarming morbidity rates. Socio-economic 
conditions are poor, resources are scarce and the philosophy behind 
primary health care is still, to a certain extent, misunderstood in some 
countries. The situation is often compounded by natural and man-made 
disasters. These countries require both technical and financial support 
from the international community to aid them in their national development 
and health policies for them to attain optimal primary health care for all.
2.2 South African perspective of primary health care
Until 1994, health care in South Africa comprised a system that was highly 
fragmented, biased towards curative care and the private sector, 
inefficient and inequitable. Although the concept of primary health care 
was acknowledged in most literature locally, there were no policies to 
address its implementation in line with the contents of the Alma-Ata 
declaration. 19
The need for transformation of the health sector in South Africa saw the 
African National Congress (ANC) initiating development of an overall 
National Health Plan based on Primary Health Care approach in 1994.
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The plan was linked with the Reconstruction and Development 
Programme which involved all other sectors. Health was therefore viewed 
from a development perspective, as an integral part of socio-economic 
development plan in South Africa.19
Implementation of the National Health Plan for South Africa started in 
1994. Three levels of government are identified in the plan: national, 
provincial and district levels, each with its own responsibilities and shared 
common goal: health care provision for the people of South Africa. Health 
care delivery takes place in a decentralised manner, with the district health 
system as a vehicle for the decentralisation process. Primary health care 
facilities are clinics and they serve as the point of entry into the health care 
system. A comprehensive package of services: preventive, promotive, 
curative and rehabilitative are provided for individuals, families and 
communities at clinic level.20
The services provided by primary health care workers include: 
immunisation, communicable and endemic disease prevention, maternity 
care, screening of children, integrated management of childhood illnesses 
(IMCI) and child health care, health promotion, youth health services, 
counselling services, chronic diseases, diseases of older persons, 
rehabilitation, accident and emergency services, family planning, and oral 
health services. Patients visiting primary health care services are treated
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mainly by primary health care nurses. Patients with complications are 
referred to higher levels of care such as hospitals if the conditions cannot 
be treated at primary health care level.21
2.2.1 Primary health care services in the North West Province
The North West Province has adopted Primary Health Care as a national 
strategy to address the basic health care needs of the population. The 
primary health care strategy is also pursued as part of socio-economic 
development.22
Primary health care services are brought nearer to the people through a 
decentralised system of district health. The district health system 
encourages participation of local communities. This has been 
strengthened by the launching of governance structures in the form of 
district committees, clinic committees and hospital boards.23
The province is also engaged in a continued process of forging 
partnerships with other sectors and other Departments that impact on 
health. This strategy ensures a holistic approach to primary health care 
and health care in general. It is hoped that the partnership against 
HIV/AIDS which is currently being strengthened will in the long run benefit 
other programmes such as immunisation.24
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2.3 International perspective of Haemophilus Influenzae Type B .
Children represent the most vulnerable segment of the population in any 
society. Promoting children’s good health is one vehicle through which 
social development can be achieved.25 Immunisation has proven to be the 
most cost effective way of preventing childhood communicable diseases 
responsible for high morbidity and mortality particularly in developing 
countries.
One of the major causes of morbidity and mortality haunting developing 
world today is Haemophilus Influenzae Type B disease. This comprises a 
variety of serious and potentially life threatening diseases among which 
are Hib pneumonia and meningitis in infants and children under the age of 
5 years. 7 It is reported that safe and effective conjugated vaccines have 
been developed and licensed for use in several industrialised countries 
where they have dramatically reduced the incidence of Hib disease 
especially meningitis.13
According to a Summary of Notifiable Diseases of USA 199 7 26 an 
estimated 20 000 cases of Hib invasive diseases among children occurred 
annually prior to Hib vaccine licensure in 1987 in the United States of 
America. The dramatic decline was attributed to the introduction of the 
Hib vaccine to children of pre-school age. To that effect, a total of 260 
cases of Haemophilus invasive disease among children aged less than 5
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years were reported in 1997. Of the 260 children, 82 (41%) for which 
serotype was known were type B. Forty-two (51%) were aged less than 6 
months, which means they were too young to have completed a three 
dose primary Hib vaccination. However, 27 (68%) of the 40 children who 
were old enough (6 months and above) to have completed a three dose 
primary series before they developed Hib invasive disease were 
incompletely vaccinated or their vaccination status were unknown. These 
cases might have been prevented with age appropriate vaccination.26
According to WHO Global Programme for Vaccines and Immunisation 
Report, priorities for research and development related to prevention of 
Hib disease in developing countries were addressed in March 1996. 
Subsequently the possibility of introducing Hib vaccine into the EPI 
schedule formed the main discussion of an international meeting held in 
Bali, Indonesia in December 1996. The results from two clinical trials 
performed in the Gambia and Chile showed 80% to 100% efficacy of 
conjugated Hib vaccine against Hib pneumonia and 90% to 95% against 
all types of invasive Hib diseases. The findings also showed a significant 
reduction in nasopharyngeal carriage. “These findings have fuelled 
interest in the wider introduction of Hib conjugate vaccine into routine 
immunisation programmes in developing countries” ,25
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While the vaccine was shown to be efficacious in the prevention of Hib 
pneumonia according to The Gambian trial, it was also interesting to 
reveal that it had an impact on the overall incidence rate of pneumonia as 
an indirect measure of the true incidence of Hib pneumonia in the 
community.4
Kim Mulholland, leader of the study team, is reported to have been excited 
by the results of the trial, that the vaccine reduced the incidence of all 
forms of pneumonia by 21%. This, according to him tells us not only that 
the vaccine works, but for the first time gave an indication that in a third 
world setting, one case in five of pneumonia could be due to Hib.4 The 
Gambia trial conducted in the even more difficult conditions of a poor 
African country, according to Mark Steinhoff of Johns Hopkins University, 
strengthened the case for not delaying the introduction of routine Hib 
immunisation in developing world. In the Gambia, deliberations on key 
issues regarding the introduction of the vaccine in the national 
immunisation programme started in October 1996 in a meeting held with 
all Hib conjugate vaccine producers.4
2.4 South African perspective of Haemophilus Influenzae Type B.
In South Africa, like in other developing countries, little was known about 
the epidemiology of the Hib infections until 1993, when two studies were 
conducted in Cape Town, one on carriage of Hib in Cape Town 3 children
28
and the other one on epidemiology of Hib infections in Cape Town.27 The 
conclusion drawn from the Hib carriage study was that carriage of Hib in 
normal children in Cape Town is similar to that reported from other 
developing countries.3
The study on the epidemiology of Hib generated information necessary for 
decision making with regard to the introduction of routine Hib 
immunisation in Cape Town. National extrapolations were made from this 
study to the fact that about 5 729 children in South Africa suffer from Hib 
diseases annually and 1 in 11 with Hib die. This prospective study 
documented that invasive Hib infections is a significant problem in Cape 
Town with Hib infections accounting for 86.5% of invasive cases.27
The observation of the overall clinical disease patterns in South Africa 
suggests that Hib infection accounts for 70% of pneumonia cases, 24.2% 
of meningitis cases, 2.9% of septicaemia cases and 2.9% of other Hib 
diseases. Available data from the notification system indicate that a total 
of 262 cases of Hib disease was reported during the period 1994 to 1998 
to the national Department of Health (table 3). 14 deaths were reported 
over the same period.28
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Table 3: Number of Hib disease cases notified in South Africa: 
1994-1998.
Year
Number 
of cases
1994 43
1995 52
1996 65
1997 49
1998 53
Total 262
Source: Epidemiological Comments 1999:1(13):3.
The provincial breakdown is shown in figure 1. No cases were reported 
from the Free State and Northern Cape Provinces.
Figure 1: Reported cases of Hib 
disease by province: 1994-1998
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On the basis of the international experience with regard to safety, efficacy 
and effectiveness of the Hib vaccine, South Africa undertook to introduce 
it routinely as part of the Expanded Programme on Immunisation (EPI) 
schedule. The Hib vaccine was thus introduced nationwide in the 
immunisation schedule with effect from 1 July 1999.13
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2.5 Hib vaccine efficacy
A double blind randomised trial was conducted in the Gambia to assess 
the efficacy of the Hib conjugate vaccine for the prevention of meningitis, 
pneumonia and other invasive diseases due to Hib. The efficacy of the 
vaccine for the prevention of all invasive diseases after 3 doses was 95%. 
For the prevention of Hib pneumonia after two or three doses it was 
100%.4
In the United States the protective efficacy of two or more doses of Hib 
vaccine among children aged 2 to 18 months was 86%.29 Other 
serological studies indicate that there are several serological parameters 
associated with Hib vaccine efficacy in infants. They also state that the 
immune response to different Hib vaccines varies both quantitatively and 
qualitatively.30 In the study of the Valencian community of Spain, the Hib 
vaccine efficacy was shown to be 90.6%. The Australian study estimated 
the vaccine efficacy at 80% for Aboriginal children.31
2.6 Vaccine identification and handling
The formulation used is that of DTP-Hib combined vaccine which is given 
as part of primary vaccination series at 6, 10 and 14 weeks at the same 
time with polio and hepatitis B vaccines. No catch up of older children was 
done. Thus a child having had received all the three doses of DTP of the 
primary series was regarded as old.13
The Hib component of the vaccine is a white powder which contains Hib 
particles conjugated to a protein. The DTP component is a liquid which 
contains diphtheria, tetanus toxoid and killed pertussis. The DTP-Hib 
combined vaccine is obtained by reconstituting the lyophilised Hib 
component with the liquid DTP component. The type of formulation used 
may change from time to time depending on what is available on tender. 
Studies have, however, shown that different formulations have similar 
effects.13
In order for the vaccine to maintain its scientifically proven properties, 
namely, safety, efficacy and effectiveness certain procedures need to be 
adhered to. With regard to safety it is necessary to ensure that only the 
vaccine is given to the child and not micro-organisms. Aseptic techniques 
therefore need to be adhered to during vaccine administration process.32 
According to the “guidelines for vaccine handling at all levels 1997 33 only 
a potent vaccine can be effective. Introducing new and expensive 
vaccines is unlikely to be worthwhile unless we can assure the 
maintenance of potency and quality. The DTP-Hib vaccine, like any other 
vaccine is heat sensitive and should always be stored at a temperature of 
between 2 and 8 degrees Celsius.33
32
The vaccine components or reconstituted vaccine must not be frozen 
according to the cold chain and immunisation operations manual 1997. 33 
The Expanded Programme on Immunisation policy guidelines require that 
the temperature of every vaccine refrigerator be read and recorded twice 
daily on the temperature chart so that any deviations from the normal can 
be detected timeously and appropriate action be taken. Cold boxes should 
be used as an alternative cold chain maintenance measure in cases of 
power failure.33
The EPI/SA 1999 13 policy stipulates that a reconstituted vial of DTP-Hib 
vaccine may be used in subsequent immunisation session for a maximum 
period of 7 days provided that the vaccine has not expired, it is stored 
under the correct temperature and is not contaminated.
In the North West province all vaccinators were trained on all 
requirements for handling the vaccine as discussed. The new vaccine is 
thus expected to perform well like it did in other developing countries (The 
Gambia, Chile and Uruguay). The reason for bringing in handling of the 
vaccine is because the whole situation as discussed may obscure the 
impact of the vaccine. The potential confounders in this study such as cold 
chain were thus controlled.
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CHAPTER 3
METHODOLOGY
3.1 Study design
A descriptive study with an analytic component involving retrospective 
record review was conducted. Comparison was made with regard to the 
incidence of both clinical pneumonia and meningitis before and after 
introduction of the Hib vaccine. The periods compared were 1 November 
1998 to 30 April 1999 and 1 November 1999 to 30 April 2000 for 
pneumonia. For meningitis they were 1 November 1998 to 31 July 1999 
and 1 November 1999 to 31 July 2000.
3.2 Study population.
The study population was all children under the age of 1 year whose place 
of residence was in the Klerksdorp district at the time of the study. The 
reason for recruiting children under the age of 1 year was that Hib disease 
is reported to be more common in this age group than others.
3.3 Study sample
Children recruited to the study were those under the age of 1 year 
admitted at Tshepong hospital, which is a public hospital serving the 
whole population using level 1 public sector health services in the 
Klerksdorp district. The reason for choosing this district was that it is one
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of the districts in which good quality of care has been ascertained. 
Therefore all factors which could impact negatively on effectiveness of the 
Hib vaccine such as cold chain maintenance were well under control in 
this district. Hib disease causes serious illness and in most cases children 
have to be hospitalised for treatment. However, since patients on medical 
aid did not participate in the study, the sample size may not be 
representative of the entire population of less than 1 year in the district.
The sample consisted of all children aged less than 1 year with a clinical 
diagnosis of either pneumonia or meningitis, admitted at Tshepong 
hospital during the chosen 6 and 9 months periods respectively before or 
after implementation of the Hib vaccine .
Pilot study
A pilot study was conducted in February 2000 following receipt of the letter 
of permission from the management of Tshepong hospital to conduct the 
study at the site. Different periods from those chosen for the study were 
used. The pilot study aimed at checking the adequacy of the checklist, 
availability and completeness of records and the time schedule for data 
collection.
Three months were reviewed during the pilot study. These were 01 July to 
30 September 1998 and 01 July to 30 September 1999. In addition to
data collection for the pilot study, availability of the admission registers to 
be reviewed during the study was checked. Recording of the immunisation 
status was also checked for the period November 1999 to February 2000.
The pilot study revealed that a total of 123 cases of pneumonia under the 
age of 12 months were admitted at the hospital during the 3 months in 
both periods. 58 (41.1%) cases were admitted in 1998 and 65 (52.8) 
cases in 1999. Regarding meningitis there was a total of 4 cases, 3 (75%) 
of whom occurred in 1998 and 1 (25%) in 1999. Age was missing in the 
records for 2 cases of pneumonia and meningitis cases had all the ages 
recorded. All other variables were recorded for all cases in both 
conditions.
The pilot study further revealed that until May 1999, both Tshepong and 
Klerksdorp hospitals were running paediatric units. The process of 
rationalisation had since combined the two to form one unit at Tshepong 
hospital. It therefore became reasonable for the researcher to review 
registers of both hospitals for a complete picture of the incidence of 
pneumonia and meningitis before introduction of the Hib vaccine for the 
period under review.
The checklist was found to be adequate, admission registers of both 
hospitals were available for the period 01 November 1998 to 31 July 1999. 
The register for the period after the Hib vaccine implementation was also
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available and was completed on a daily basis in respect of personal 
details of children admitted to the ward. The immunisation status was 
being recorded in cases where the immunisation card was available and 
the report from the ward nursing sister revealed that mothers were 
encouraged on a continuous basis to bring along the immunisation cards 
whenever a child was admitted to the hospital. . The original time schedule 
for data collection was adhered to since it was found to be reasonable. No 
adjustment was thus made either in the data collection tool or time frames 
for data collection.
3.5 Measurement
Measurement tools
A checklist was designed to collect data from variables that were 
investigated.
Variables
The variables investigated were: age, diagnosis, date of admission, 
immunisation status, number of Hib doses received and the dates doses 
were given.
Data collection techniques
Preparations for data collection were done within the context of EPI 
management since the researcher is the manager of the EPI programme
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in the province. An existing system of presenting a child’s immunisation 
card with every consultation or admission to hospital was strengthened at 
the facility after the Hib vaccine implementation. This system only requires 
screening of the immunisation card so that the child can be immunised on 
discharge if there are missing immunisations. An additional requirement of 
documenting the immunisation status of Hib and the dates of 
immunisation was temporarily introduced at Tshepong hospital paediatric 
ward and it was not without limitations. Other variables from which data 
collection was intended were readily available from the admission register.
Data collection process
The data collection process was undertaken during the period May to July 
2000. All data were collected by the researcher. The nursing sister in 
charge of the paediatric ward was requested to oversee documentation of 
the required information on the Hib immunisation status of every child 
under the age of 1 year admitted to the ward. Ward admission registers 
were accessed from the paediatric ward at Tshepong hospital. A data 
collection sheet was used to collect data from each patient admitted at the 
hospital during periods under review (see annexure A). Records were 
reviewed retrospectively to identify required variables.
The admission registers were reviewed for the periods 1 November 1998 
to 30 April 1999 and 1 November 1999 to 30 April 2000 for pneumonia.
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Periods were extended to 31 July 1999 and 31 July 2000 for meningitis. 
Based on the previous years admissions of both pneumonia and 
meningitis, it was likely to get enough cases of pneumonia within 6 months 
whereas more time was needed for meningitis cases because of few 
numbers of cases in the previous years. This is the reason why the period 
for meningitis was extended by 3 months.
Validity and reliability
The data collection was done by the researcher and measures were taken 
to minimise errors. Cross checking was done in all cases of doubtful 
information. Patient registration (hospital) numbers were used to check for 
duplications.
3.6 Data capturing and analysis
The data entry screen was designed in Epilnfo 6 according to each 
variable. Data was captured and later frequency tables were generated for 
each category of variables. Excel was used to produce tables and graphs 
for presentation. Incidence rates, relative risks, and p values were 
calculated for various categories of data using the stata programme.
The denominators used to calculate the incidence rates were the 1996 
population census for children under the age of 1 year in the Klersdorp 
district. Projections were made for 1999 and 2000. These projected
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figures were adjusted for 6 months and 9 months for pneumonia and 
meningitis respectively. The 1999 and 2000 projected and adjusted 
population figures were thus used as the denominators for the periods 
before and after the Hib vaccine implementation respectively.
The incidence rate of pneumonia was expressed per 1000 population 
while that of meningitis was expressed per 10 000 population due to the 
small number of cases in meningitis.
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CHAPTER 4
RESULTS
4.1 Age distribution of cases
Pneumonia
There were 323 cases of pneumonia under the age of 12 months. Of 
these, 185 (57.3%) cases were admitted before the Hib vaccine 
implementation and 138 (42.7%) were admitted after implementation of 
the vaccine (table 4).
Table 4: Age distribution of pneumonia cases under the age of 12 months 
before and after Hib vaccine implementation: Klerksdorp district
Age in 
months
1998/99 1999/2000
Number 
of cases Percentage
Number of 
cases Percentage
0 10 5.4 7 5.1
1 24 13.0 19 13.8
2 19 10.3 22 15.9
3 41 22.2 24 17.4
4 15 8.1 18 13.0
5 20 10.8 10 7.2
6 13 7.0 8 5.8
7 10 5.4 6 4.3
8 5 2.7 9 6.5
9 8 4.3 7 5.1
10 13 7.0 4 2.9
11 7 3.8 4 2.9
Total 185 100 138 " lo o
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Meningitis
There were 53 cases of meningitis under the age of 12 months. Of this 
total, 31 (58.5%) cases were admitted before and 22 (41.5%) cases were 
admitted after the vaccine implementation. Table 5 shows the age 
distribution of cases.
Table 5: Age distribution of meningitis cases under the age of 12 months 
before and after Hib vaccine implementation: Klerksdorp district
Age in 
months
1998/99 1999/2000
Number 
of cases Percentage
Number of 
cases Percentage
0 5 16.1 0 0
1 1 3.2 0 0
2 3 9.7 2 9.1
3 5 16.1 4 18.2
4 3 9.7 1 4.5
5 3 9.7 3 13.6
6 2 6.5 3 13.6
7 0 0 1 4.5
8 1 3.2 2 9.1
9 1 3.2 3 13.6
10 3 9.7 1 4.5
11 4 12.9 2 9.1
Total 31 100 22 100
4.2 Incidence rates
Pneumonia
The incidence rate of pneumonia cases in the period before Hib vaccine 
implementation was 54.3 per 1000 population compared to 39.6 per 1000
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in the period after implementation of the vaccine. (P value=0.0048) The
relative risk was 1.37 (confidence interval: 1.09 -  1.72). The monthly
incidence rates for both periods under review are compared in table 6.
Table 6: Monthly incidence rates of pneumonia cases under the age of 12 
months: Klerksdorp district: 1998/99 and 1999/2000.
Month
1998/99 1999/2000
Number of
cases
Incidence 
rate per 1000
Number of 
cases
Incidence 
rate per 1000
November 37 65.2 20 34.4
December 30 52.9 33 56.8
January 26 45.8 20 34.4
February 21 37.0 26 44.8
March 30 52.9 16 27.6
April 41 72.2 23 39.6
Total 185 54.3 138 39.6
Meningitis
The incidence rate for meningitis was 60.7 per 10 000 population in the 
period prior to Hib vaccine implementation as compared to 42.1 per 
10 000 in the period after the vaccine implementation. (P value=0.19). The 
relative risk was 1.44 (95% confidence interval: 0.81 -  2.61). Table 7 
shows the monthly incidence rates.
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Table 7: Monthly incidence rates of meningitis cases under the age of 12 
months: Klerksdorp district: 1998/99 and 1999/2000.
Month
1998/99 1999/2000
Number of 
cases
Incidence 
rate per 
10000
Number of 
cases
Incidence 
rate per 
10000
November 5 88.1 4 68.9
December 2 35.2 3 51.7
January 7 123.3 1 17.2
February 3 52.9 1 17.2
March 4 70.4 2 34.4
April 5 88.1 1 17.2
May 5 88.1 6 103.3
June 0 0 2 34.4
July 0 0 2 34.4
Total 31 60.7 22 42.1
4.3 Laboratory confirmed cases of Hib meningitis
During the period under review, 580 specimens from patients of all ages 
were submitted to Tshepong hospital laboratory for meningitis test before 
the Hib vaccine implemention. After implementation of the vaccine, 1 100 
specimens were submitted to this laboratory. 15 (2.6%) specimens were 
positive for all types of meningitis for the period before Hib implementation 
as compared to 28 (2.5%) positives after Hib implementation.
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Of the 15 positive specimens before Hib implementation, 4 (26.7%) were 
positive for Hib meningitis. Of the 4 cases, 3 were under the age of 1 year, 
and 1 was 6 years old. In the period after Hib vaccine implementation the 
number of positive Hib meningitis cases were also 4 (14.3%). There was 
no case under the age of 1 year among them (see annexure).
The substantial increase in the number of tests sent to the laboratory 
before vaccine implementation and after implementation was due to 
merging of the former Klerkdorp hospital laboratory and the Tshepong 
hospital laboratory into one laboratory based at Tshepong hospital since 
April 1999. It was difficult to obtain information for the age under review 
as the system could only generate individual patient information and not a 
summary of age groups of specimens sent to the laboratory.
4.4 Hib immunisation status of children under the age of 12 months.
Of the 160 children under the age of 12 months admitted with pneumonia 
and meningitis (138 & 22 respectively) after implementation of the Hib 
vaccine, 17 were not immunised with the Hib vaccine and the 
immunisation status of 14 children was not known because their 
immunisation cards were not available for screening at the time of their 
admission. A total of 129 (80.6%) children under the age of 12 months had 
received all the dose(s) of the Hib vaccine required by their ages. Table 8
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shows the immunisation status of children with pneumonia and meningitis 
for all doses combined.
Table 8: Immunisation status of children under the age of 12 months
admitted at Tshepong hospital after introduction of the Hib 
vaccine.
Age group 
in months
Frequency Number of
children
immunised
Number of 
children not 
immunised
Immunisation 
status not 
known
0 - 2 50 42 6 2
3 - 5 60 49 4 7
6 - 8 29 23 3 3
9-11 21 15 4 2
Total 160 129 (80.6%) 17 (10.6%) 14 (8.8%)
4.5 The number of doses and interval between doses for immunised 
children admitted with either pneumonia or meningitis.
The number of doses received were as follows:
64 (49.6%) children received 1 dose each.
10 (7.8%) children received 2 doses each and
55 (42.6%) children received 3 doses each. The immunisation coverage 
for children who received all the three doses was 34.4%.
The interval between doses was 4 weeks in all cases of immunised
children.
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4.6 Commonly encountered variable 
4.6.1 HIV status of cases
Although there was no plan in the protocol to collect data on the HIV 
status of children admitted with either pneumonia or meningitis, this 
variable appeared frequently during the process of data collection and the 
researcher thought it was not only interesting, but it would assist in arriving 
at conclusions as it was considered to be one of the confounding factors. 
Since the data was readily available it was collected.
It was interesting to note that 40 (18.5%) of the 216 cases of pneumonia 
and meningitis combined during the period 01 November 1998 to 31 July 
1999 were HIV positive. During the period 01 November 1999 to 31 July 
2000, there were 58 (36.3%) HIV positive cases of all the 160 cases of 
pneumonia and meningitis combined.
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CHAPTER 5
DISCUSSION
Pneumonia
This study has shown a significant difference between the two periods 
compared with regards to the clinical incidence of pneumonia cases under 
the age of 1 year admitted at Tshepong hospital (P value = 0.0048). The 
difference showed a decline in the number of cases after implementation 
of the Hib vaccine.
The results showed that before the Hib vaccine implementation, children 
under the age of 1 year had 1.37 chances of contracting pneumonia than 
in the period after Hib vaccination.
The results of this study on pneumonia are consistent with those of the 
Gambia study on assessment of the efficacy of a Hib conjugate vaccine 
for the prevention of pneumonia, meningitis, and other invasive diseases 
due to Hib. The Gambia study showed that the Hib vaccine was highly 
effective in preventing pneumonia and meningitis due to Hib after the 
three doses are given in infancy. The second and third doses provided 
100% protection efficacy for pneumonia cases. The protection efficacy 
was 95% for all other invasive diseases. There was a 21% reduction in the 
radiologically defined pneumonia. Good immunogenicity was associated 
with efficacy, as had been found in industrialised countries.4
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Despite the consistent results, the methodology used in this study, 
however, differs from the one used in the Gambia study, and the 
objectives were also different. The other important difference is that the 
Gambia study was conducted countrywide while this study was conducted 
in only one district. The researcher is not aware of any previous study 
similar to this one globally including South Africa.
Other studies which showed consistent results with this one are trials of 
two developing countries, Gambia and Chile which showed 80% to 100% 
efficacy of conjugated Hib vaccine against pneumonia and 90% to 95% 
against all types of invasive Hib diseases.4
Meningitis
In respect of meningitis this study has also shown a difference in the 
number and incidence rate of meningitis in the two periods compared. The 
statistical test (p value = 0.19), however, showed that the observed 
difference was not significant. This means that the observed decline in 
the incidence of cases was a result of chance.
The results of this study on meningitis were therefore not consistent with 
those of the Gambia and Chile. The researcher is not aware of any studies 
that are consistent with this one regarding the impact of Hib on the 
incidence of meningitis. Other factors which might have played a role are
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not known. The impact of HIV infection was considered. Could it be due 
to the limitations in the methodology? This needs further investigation.
The available literature does not comment on the impact of HIV on 
seroconversion or incidence of vaccine preventable diseases. However, 
the study conducted at Chris Hani Baragwanath hospital revealed that 
paediatric HIV infection has changed the profile of paediatric admission 
diagnoses and increased hospital mortality. HIV negative children on the 
other hand showed declining rates of vaccine preventable diseases.34
According to the USA study the clinical efficacy of the currently used 
vaccines in the HIV infected individuals is not well defined. It, however, 
appears that patients in the earlier stages of infection are more likely to 
mount a protective antibody response than those in the later stages.30
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Immunisation coverage
The immunisation coverage for children who received all the three doses 
of the vaccine was 34.4%. The cumulative proportion of children 
immunised with 1st 2nd and 3rd doses was 80.6%. It is believed that this 
immunisation status provided significant protection against pneumonia.
Comparison of laboratory confirmed meningitis cases 
Further consideration was given to the laboratory confirmed Hib meningitis 
cases during the periods under review. The results showed that before Hib 
vaccine implementation there were 3 cases of laboratory Hib confirmed 
meningitis cases under the age of 1 year. After implementation of the 
vaccine no cases under the age of 1 year were reported.
If one was to use the argument of the laboratory confirmed Hib 
meningitis, it is more likely that the Hib vaccine had similar impact on 
meningitis as it had on pneumonia.
Limitations
The limitations in this study were as follows:
Validity and reliability
Though the researcher collected the data and cross checked all entries, 
the extent of accuracy of records reviewed could not be ascertained.
Timing of the study
The first cohort of children who were six weeks old and entered the Hib 
immunisation on 1 July completed their third dose in September or end of 
August. The data collection process started on 1 November. This was 
about one month after the first cohort had completed their third dose. This 
period is considered to be short given that there was only one cohort of 
children who received the required three doses of the vaccine when the 
data collection process started. As a result of this, not all children had 
completed their three doses at the time of the study and the findings were 
based on different number of doses received instead of three doses
Sample size
The sample size for meningitis was small, 31 cases and 22 cases before 
and after implementation of the vaccine respectively. The small sample 
size of clinical meningitis cases made it difficult to draw conclusions.
Generalisation
As stated in the introduction, about 21% of the population in the 
Klerksdorp district belong to the medical aid schemes. This proportion of 
private patients were not included in the study. Secondly, the study was 
conducted in a public sector facility which mainly caters for patients not on 
medical aid, predominantly blacks. The implication is that other racial 
groups were underrepresented in the study and the researcher might have
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lost on a number of other important unique features such as incidence of 
pneumonia and meningitis among whites and their compliance with 
immunisation.
Further, the study relied on admitted cases only. This means that not all 
cases of pneumonia and meningitis have been detected. Although this 
does not affect the proportion of cases in the two groups, it gives a false 
impression of the number of cases in the population.
CHAPTER 6
CONCLUSIONS
The proportion of children who received at least one dose of the vaccine 
was 80.6% among admitted children with pneumonia and meningitis at 
Tshepong hospital. It is believed that the decline in the incidence of 
pneumonia was due to the impact of the Hib vaccine.
While the decline in the incidence of meningitis was not statistically 
significant, the impact of the Hib vaccine in reduction of cases of 
meningitis cannot be excluded at this level. Other important factors that 
might have hindered the impact of the vaccine on the incidence of 
meningitis need further investigation. These factors include, among 
others, the possibility of a small sample size bias and the impact of HIV 
infection.
Further, the absence of laboratory confirmed Hib meningitis cases under 
the age of 1 year after Hib implementation against 3 cases of the same 
age group before implementation of the vaccine strengthens the argument 
in favour of the Hib vaccine for meningitis.
On the basis of the significant decline in the incidence of pneumonia, it is 
concluded that the new Hib vaccine reduced the incidence of pneumonia
by 14.7 percent in the Klerksdorp district within a period of 10 months after 
its implementation. Its positive impact on meningitis could, however, not 
be detected in this study, probably due to other confounding factors.
While the findings of this study are not conclusive, they are suggestive 
that the Hib vaccine had a significant decline on the incidence of 
pneumonia in the Klerksdorp district. Regarding the incidence of 
meningitis, further research is needed to investigate the impact of the Hib 
vaccine on this disease.
Limitations in the methodology and the possibility of confounding factors 
are acknowledged.
Despite these limitations, it is believed that this research project has 
generated important information which provides the basis for future 
research in this phenomenon. Against this background, it is important to 
make recommendations that may form the basis of further research.
RECOMMENDATIONS.
It is recommended that:
A similar study be conducted in the North West province after 3 years of 
implementation of the Hib vaccine when there will be enough population to
form the basis of comparison in respect of the immunisation status and 
exposure to Hib disease.
The impact of Hib vaccination be measured on a routine and continuos basis 
using laboratory surveillance for Hib meningitis and other available 
information.
Studies be conducted in South Africa to identify the vaccination and 
programme factors that may hinder the impact of the Hib vaccine.
Given that there was no significant decline in the incidence of clinical 
meningitis cases, studies be conducted in South Africa to determine the 
impact of HIV infection on the success of the immunisation programme with 
main emphasis on the possibility of its adverse effects on seroconversion 
rates.
DISSEMINATION OF FINDINGS
Copies of this report will be distributed to all stakeholders including, managers 
in the provincial and district offices of the North West Department of Health, 
Tshepong hospital management and staff at Tshepong paediatric ward.
Presentation of results will also be made in provincial research conferences 
planned to be held annually.
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ANNEXURE B
ANNEXURE 1
IMPACT OF HIB VACCINE
CHECKLIST
Hosp tal number:
2. Residential address:
Date of b rth
D D M M Y Y
4. Age in months:
5. Date of admission:
D D M M Y Y
6. Diagnosis
7. Hib immunisation status:
Immunised Not immunised
8. Date(s) immunised and interval between doses:
Date dose 
received
Age in weeks Interval between doses 
in weeks
1 dose -
2 doses
3 doses
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PROJECT The Impact of Haemophilus Influenzae Type B 
(Hib) Vaccine On Pneumonia And Meningitis 
Among Children Under The Age if 1 Year In 
Klerksdorp District of The North West 
Province
INVESTIGATORS
DEPARTMENT
C Sebekedi
Community Health, North West Dept of Health
DATE CONSIDERED 991001
DECISION OF THE COMMITTEE *
Approved unconditionally
DATE 991014 CHAIRMAN........................................ (Professor P E Cleaton-Jones)
* Guidelines for written "informed consent" attached where applicable.
c c Supervisor: Mr c  vundile 
Dept o f ,
Works2\lain0015\HumEth97.wdb\M
DECLARATION OF INVESTIGATOR(S)
To be completed in duplicate and ONE COPY returned to the Secretary at Room 10001, 10th Floor, 
Senate House, University.
l/we fully understand the conditions under which I am/we are authorized to carry out the abovementioned 
research and l/we guarantee to ensure compliance with these conditions. Should any departure to be 
contemplated from the research procedure as approved l/we undertake to resubmit the protocol to the 
Committee.
DATE .......SIGNATURE ...............................
PROTOCOL NO.: M 990941
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2735
1999-12-18
Dear Mrs Sebekedi
Approval of protocol entitled 'The impact of Haemophilus Influenzae B (Hib) vaccine on pneumonia 
and meningitis among children under the age of 1 year in the Klerksdorp district of the North West 
Province
I should like to  advise you that the protocol and title that you have submitted for the degree of Master 
Of Public Health (Part-Time) have been approved by the Postgraduate Committee at its recent meet­
ing. Please remember that any amendment to this title has to be endorsed by your Head of Department 
and formally approved by the Postgraduate Committee.
Mr C Vundule has/have been appointed as your supervisor/s. Please maintain regular contact with your 
supervisor who must be kept advised of your progress.
Please note that approval by the Postgraduate Committee is always given subject to permission from 
the relevant Ethics Committee, and a copy of your clearance certificate should be lodged with the 
Faculty Office as soon as possible, if this has not already been done.
Yours sincerely
JO Mainwaring (Mrs) 
Faculty Officer 
Faculty of Health Sciences
Telephone 647-2075/2076
Copies - H ead o f  D epartm en t_____ Supervisor/s
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Republic of South Africa
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Ms Calvinia Sebekedi 
Department of Health 
North West
Dear Ms Sebekedi,
Private Bag X2068 
Mmabatho 
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Tel: (018) 387-5284/5 
Fax: (018) 387-5334 
e-mail: mmanong_ntoane@nwpg.org.za
RE: PERMISSION TO CONDUCT RESEARCH IN THE NORTH WEST PROVINCE
The Departmental Research Committee recently reviewed your research proposal entitled 
The impact o f haemophilus influenzae type B (Hib) vaccine on pneumonia and meningitis 
among children under the age o f 1 year in Klerksdorp district o f the North West province, 
and wishes to inform you that permission has been granted to conduct the study, 
subject to the fo llow ing conditions:
i. The Ethics/Research Review Committee of your academic institution has 
approved your proposal,
ii. The Department will not be responsible for any costs associated with the research 
project,
iii. That on completion of the research project, a copy of the research report (or 
dissertation or thesis) w ill be submitted to the Department.
A ttached are comments from the Departmental Research Committee that you should 
address before conducting your research project.
Any enquiries and correspondence regarding the research should be addressed to Mr 
Caesar Vundule or Mrs Rebone Gcabo (tel. (018) 3875213/6).
Yours sincerely,
M.C. NTOANE 
Deputy Director General
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Re:Ethics Committe approval for your research on the efficacy of Hib vaccine.
The ethics com m ittee o f  the com plex met on 7/01/2000 and considered your application.
The com mittee decided to approve your application. The study is approved for a  period o f  
m onths from  the date o f  approval. A report o f  your study should be subm itted to the ethics 
com m ittee at the end o f  3 months.
All relevant patient files used for the study can be accessed from archives after following the 
procedures o f  the departm ent. The files should be returned and may not be taken  out o f  the 
hospital.
D r.A .H .W adee 
H ospital M anager 
Chairman,Ethics Com m ittee
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